T
he dream of preventing cancer with a vitamin pill is rapidly evaporating. Over the past few months, results from clinical trials and observational studies report no benefit -and in a few cases, possible harm -from supplementation with several micronutrients, including vitamins C, D, and E; selenium; calcium; and folate.
The fi ndings have sobered investigators in the fi eld of chemoprevention and led to a wholesale reevaluation of the methods used to assess possible benefi ts of vitamins and minerals and to prioritize them for defi nitive testing.
"I think there is a lot of disappointment," said Peter Gann, M.D., Sc.D., a physician -epidemiologist at the University of Illinois at Chicago who studies nutrition and cancer. "When these expensive trials were being designed, there was a lot of hope. Some pretty heavy bets were being placed on those interventions."
In light of the results, investigators anticipate more laboratory work and smaller, exploratory human studies designed to probe exactly how vitamins and minerals affect tumor formation and growth. They also foresee more research geared toward determining whether certain subpopulationssay, those with a certain genetic profi le -might still benefi t from supplementation.
But for preventing cancer in the general population, the prospects look bleaker than ever. "Almost unbelievably, none of the studies has shown a benefi t, and a couple even suggest the potential for harm," said Philip Taylor, M.D., Sc.D., of the National Cancer Institute's Genetic Epidemiology Branch. "Given these results, it's hard to be encouraged about micronutrient trials in well-nourished Western populations." However, there is one bright spot. As reported in this issue of the Journal, a study led by Taylor and conducted in China found that a supplement containing selenium, vitamin E, and ␤ -carotene reduced mortality from gastric cancer. Moreover, the benefi t continued for 10 years after the volunteers stopped taking the supplement. "This represents the longest durability of effi cacy observed … in any prevention trial, including drug trials," Taylor said. But he and others point out that the study population, in remote Linxian, China, ate a poor diet and most likely suffered defi ciencies of the nutrients tested.
" N E W S published in January, highlighted a nonstatistically signifi cant increase in prostate cancers among men who took vitamin E. Over 5 years, 4.93% taking vitamin E developed prostate cancer, compared with 4.36% among those taking placebo. Another randomized trial, the Aspirin/ Folate Polyp Prevention Study, found a statistically signifi cant excess of prostate cancers in the men who received folic acid, a form of folate. Over 10 years, 9.7% of men taking folic acid developed prostate cancer, contrasted with 3.3% in the placebo group. And going back to the late 1990s, two other randomized studies showed that supplements of ␤ -carotene, a form of vitamin A, increased the risk of lung cancer in smokers.
The emerging picture is complex. "Folate defi ciency increases cancer risk, and excess folate also increases cancer risk. We know that," said Milner. "We also have some evidence with calcium, with vitamin B, with selenium, certainly historically with ␤ -carotene. At low ends there may be some benefi ts, but too much is a harm."
Potter, who has long opposed large single-or dual-agent chemoprevention cancer trials, said, "If you look at a lot of the trials we've done, we've used [high] doses on the basis that if some is good, more is better." But, he pointed out, the fi ndings from the Linxian trial suggest that, instead, a "physiologic" dose -something close to the U.S. Department of Agriculture's recommended daily intake -may be optimal. Or, as Milner put it: "Too much of a good thing isn't necessarily good, is it?"
Rethinking Study Design
In the wake of the fi ndings, researchers expect no new large studies of vitamins and minerals for cancer prevention. "It's going to be very hard for somebody to get fi nancial support for a large phase III trial," said Gann.
Instead, the fi eld is refocusing on a personalized approach, said Milner, and trying to understand the individual differences in how people process vitamins and minerals.
"I think the area of genetics and personalized medicine is really going to advance this fi eld," said Mara Vitolins, Ph.D., the principal investigator for the WHI at Wake Forest University. She gives one hypothetical example: Research may uncover that some people carry a gene variant that hinders absorption of folic acid from food. Those people might then benefi t from a supplement.
The results also are pushing researchers to return to where the nutrients of interest originate -food. This idea harks back to early epidemiologic studies that showed an association between diet and cancer rates.
"The reality may be that the benefi cial effects of diet that we see pretty consistently in epidemiologic research are not 
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attributable to single compounds but may be attributable to consumption of whole foods or even patterns of foods," said Gann.
Potter said, "We need to rethink what we're doing. Vegetables are this incredibly complex mix of all these compounds, and yet we insist on trying to isolate a single agent from them."
For antioxidants, which include vitamins C and E, "there are hard lessons here, and I don't think people will be so inclined to try to isolate a single one and give it in large doses," said Gann. Oxidative stress has a positive function in the body too, he pointed out, such as helping to combat infections.
In a recent editorial accompanying the folate study ( see J. Natl. Cancer Inst. Cancer Center in Houston, suggest small dietary cohort studies with more accurate food intake assessment than that provided by the questionnaires typically used. They also point to a study they are conducting to unravel how components in broccoli might affect early development of prostate cancer. If the study shows that large amounts of broccoli do infl uence prostate tumor formation, then a larger trial of the components should move forward, they say, noting that such a model provides a more solid footing for large clinical trials of nutrients.
Potter advocates observational studies of diet that focus on the mechanisms of nutrients. And like Kristal and Lippman, he also wants small-scale intervention trials that focus on gene -nutrient and nutrient -nutrient interactions in the body -that is, studies that sort out exactly what happens when a person takes fi ve or 10 times the recommended daily intake of a vitamin or mineral.
"These are really important steps to take right now," said Potter. "We've got to work out the complexity of the whole issue."
